Destination therapy: one-year outcomes in patients with a body mass index greater than 30.

摘要: Left ventricular assist devices (LVADs) are slowly gaining acceptance as the treatment of choice in appropriately selected patients with end-stage heart failure who not transplant candidates. Obesity is a well-known risk factor for increased cardiovascular morbidity and mortality, frequently can be reason some turned down transplantation. Because this experience patients, many centers have also been reluctant to offer these an LVAD destination therapy (DT). Subsequently, 1-year outcomes obese receiving LVADs DT at our center were reviewed. Fifty-eight consecutive (83% men) implanted HeartMate XVE (n = 22) or II 36) LVAD. Patients divided into normal (body mass index [BMI] or= 30 kg/m(2), n 20) groups according their BMI. Preoperatively, there statistically significant differences (P 0.5) between groups: creatinine levels (1.4 vs. 1.5), New York Heart Association classification (1.2 1.6), survival (63% 65%). Our initial results demonstrate that morbidly contraindication may successfully undergo implantation DT.